Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.

MLA

Jung, Maria, et al. “Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.” Clinical Chemistry, vol. 65, no. 4, Apr. 2019, pp. 559–68. EBSCOhost, https://doi.org/10.1373/clinchem.2018.297549.

APA

Jung, M., Ellinger, J., Gevensleben, H., Syring, I., Lüders, C., de Vos, L., Pützer, S., Bootz, F., Landsberg, J., Kristiansen, G., & Dietrich, D. (2019). Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 65(4), 559–568. https://doi.org/10.1373/clinchem.2018.297549

Chicago

Jung, Maria, Jörg Ellinger, Heidrun Gevensleben, Isabella Syring, Christine Lüders, Luka de Vos, Svenja Pützer, et al. 2019. “Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.” Clinical Chemistry 65 (4): 559–68. doi:10.1373/clinchem.2018.297549.